Suzhou Zelgen Biopharmaceuticals Co. Ltd.SSE: 688266

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Gecacitinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis

· Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · · 3 pages · Chinese

On 6ix: 6ix.com/news/suzhou-zelgen-biopharmaceuticals-co-ltdannouncement-on-voluntary-disclosure-of-the-acceptance-of-the-new-drug-application-for-gecacitinib-hydrochloride-tablets-for-the-treatment-of-active-ankylosing-spondylitis

Release

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Gecacitinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Suzhou Zelgen Biopharmaceuticals Co. Ltd. on 6ix

Earlier from Suzhou Zelgen Biopharmaceuticals

Later from Suzhou Zelgen Biopharmaceuticals

All Suzhou Zelgen Biopharmaceuticals news releases